Navigation Links
CHOP oncologist leads first SU2C pediatric dream team
Date:4/7/2013

Philadelphia and Washington, April 7, 2013 A physician-researcher from The Children's Hospital of Philadelphia will lead the first-ever pediatric "Dream Team" solely focused on creating new treatments for the most challenging childhood cancers. Stand Up to Cancer (SU2C) and the St. Baldrick's Foundation, along with the American Association for Cancer Research (AACR), SU2C's scientific partner, announced this Dream Team today during a press conference at the AACR Annual Meeting 2013 in Washington, D.C.

John M. Maris, M.D., director of the Center for Childhood Cancer Research at The Children's Hospital of Philadelphia, and professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania, will lead the pediatric Dream Team, which will have $14.5 million in funding over 4 years, provided by SUC2 and St. Baldrick's. Crystal L. Mackall, M.D., chief of the Pediatric Oncology Branch of the National Cancer Institute (NCI), is the co-leader of the Dream Team.

The title of the research project, "Immunogenomics to Create New Therapies for High-Risk Childhood Cancers," reflects the melding of two powerful disciplines that have historically functioned independently: immunotherapeutics and genomics. The goal is to rapidly translate promising basic research into transformative, targeted treatments that will improve cure rates in children's cancer.

"The motivation for the creation of this collaborative research project is the realization that completely new strategies are needed if we are to have curative therapies for all childhood cancers," said Maris. "Our Team hopes to rapidly develop more precise and effective treatments based on the unique characteristics of each child's tumor, here focusing on the genetic changes that make the cancer cells different from the rest of the child's body."

Immunotherapeutics focuses on developing treatments that harness the body's own immune system to fight disease. Genomics, the field that analyzes the broad landscape and fine details of the genetic code in DNA, reveals potential targets for disease treatments.

At today's press conference, Emily (Emma) Whitehead and her parents Kari and Tom provided dramatic evidence of the power of these scientific tools to treat cancer. Emily, age 7, had a dramatic recovery from a relapsed form of childhood leukemia following an experimental treatment at The Children's Hospital of Philadelphia (CHOP) which used her own immune cells. Researchers from CHOP and the University of Pennsylvania genetically engineered Emily's T cells to find and destroy leukemia cells. Emily, who was featured in news stories last December, remains healthy and cancer-free, nearly a year after receiving the highly innovative therapy.

The new pediatric Dream Team addresses a crucial need in treating children's cancers. After dramatic progress throughout the last half of the 20th century, cure rates for pediatric cancers plateaued in the 1990s. "Very few new therapies have been developed for pediatric cancer in the past 20 years," said Maris. In addition, he added, current therapies for childhood cancers often have severe side effects that reduce quality of life for survivors who enter adulthood.

Hence, there is a need for new classes of treatments to improve both survival and quality of life. The researchers on the new Dream Team, said Maris, have deep expertise in the most lethal pediatric cancers, and will combine their experience and commitment to a sustained effort improve cure rates.

Realizing the ambitious Dream Team efforts, stresses Maris, will rely on the talents of many collaborators. The researchers represent seven institutions: CHOP, NCI, the Baylor College of Medicine, Seattle Children's Hospital, the University of British Columbia, the Hospital for Sick Children in Toronto, and the University of Wisconsin.

The Dream Team also includes important patient advocates: Kelly Cotter, a childhood cancer survivor; Jay Scott and Liz Scott, of the Alex's Lemonade Stand Foundation; Patrick Sullivan, of the Team Finn Foundation; and Lisa Tichenor and Mac Tichenor, of the What Would Willy Want Foundation (Quad W Foundation).

Maris draws on the internationally prominent expertise of Stephan A. Grupp, M.D., Ph.D., and Tom Curran, Ph.D., to lead the CHOP-based research programs. Grupp has developed the first highly effective childhood cancer immunotherapy, in collaboration with Carl H. June, M.D., of the Perelman School of Medicine at the University of Pennsylvania. It was Grupp's efforts that resulted in Emily Whitehead's remarkable recovery from her lethal leukemia and her attendance at the press conference today.

"We were excited to experience this great outcome with Emily," said Grupp, who added, "Although this is an early result, it offers the promise of a significant advance against this high-risk childhood leukemia. Our goal on the Dream Team is to emulate this success in treating other pediatric cancers."

Oncology researcher Tom Curran is a member of the Institute of Medicine, and was recently named to the AACR's inaugural class of Fellows of the AACR Academy. He will lead the brain tumor discovery efforts at CHOP, interacting closely with Maris's own research program in neuroblastoma. CHOP will serve as the central hub for data analysis and new therapy development across the Dream Team consortium. The full list of Dream Team leaders and investigators at CHOP can be viewed online.

The Dream Team will focus on the four most deadly pediatric cancers: malignant brain tumors, high-risk leukemias (such as the type of acute lymphoblastic leukemia that Emily Whitehead had), neuroblastomas (which affect the peripheral nervous system) and sarcomas (other tumors of bone and other tissue).

Recent research in genomics, said Maris, has shown that pediatric cancers are fundamentally different from adult cancers. Children's cancers are less likely to arise due to recurring mutations that can be countered with small molecule drugs. Instead, this Dream Team will exploit the unique feature of molecules on cell surfaces of childhood cancer cells that are not present on normal cells, and thus offer targets for treatments employing bioengineered agents working through the immune system.

In transforming this scientific knowledge into treatments, the Dream Team members will take a three-step approach. First, they will discover cell-surface molecules offering promising targets in high-risk children's cancers. Secondly, they will create immunotherapy-based proteins to attack those molecules. The third step is to carry out multi-institutional clinical trials of these treatments in children.

"The success of the program will ultimately be judged by the number of lives saved through our efforts," concluded Maris.


'/>"/>

Contact: Rachel Salis-Silverman
salis@email.chop.edu
267-970-3685
Children's Hospital of Philadelphia
Source:Eurekalert

Related medicine news :

1. Oncologist expands HPV research to anal cancer
2. Mayo study: Exercise can help cancer patients, but few oncologists suggest it
3. Boston researcher, surgical oncologist receives national award
4. TGen researcher leads distinguished international panel at genetics conference in Phoenix
5. Nottingham leads £2.6m international clinical trial into new stroke treatment
6. Research leads to better understanding of peripheral neuropathy
7. Manchester leads new international study investigating Inflammatory Bowl Disease
8. Premium Astrology Client Care Team Leads Norah Guide to New Reviews Daily
9. Inhaled betadine leads to rare complication
10. Platypus Australia Leads The Way For Summer Fashion By Launching New Range of Children’s UV Protective Swimwear
11. Frog-in-bucket-of-milk folklore leads to potential new antibiotics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , ... February 05, 2016 , ... ... setting the stage for new clinical and scientific initiatives have all marked the ... she was appointed President and CEO of the nation’s oldest cancer center, Candace ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... College President George H. Van Allen have signed a joint enrollment and degree ... a seamless pathway toward associate and baccalaureate degrees at FHU|Dickson. , The ...
(Date:2/5/2016)... ... 05, 2016 , ... The American public tends to feel uncomfortable about drinking ... regular municipal or well water. The recent experience with lead contaminated water in Flint, ... long way toward increasing public acceptance of recycled waste water as drinking water. ...
(Date:2/5/2016)... ... 05, 2016 , ... At its annual meeting held last week, the American ... National Board of Directors. Mr. McDermott succeeds former APDA Chairman, Fred Greene. , "We ... Chambers , APDA President and CEO. “Pat has tirelessly served APDA since 2001 when ...
(Date:2/5/2016)... ... February 05, 2016 , ... In sleep, when the defenses of the day ... feature of patients with eating disorders is significant self-criticism, and consequently these patients experience ... are regarded as maladaptive means for coping with this unease, but also leads to ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... CENTENNIAL, Colo. , Feb. 5, 2016  As ... about health. The multitude of recommended screenings and tests ... healthy aging a priority. However, for the majority of ... of proactive health planning. For the 37.5 million American ... time like the present to make hearing health a ...
(Date:2/5/2016)... 2016 Aethlon Medical, Inc. (Nasdaq: AEMD ), ... will be presenting at Source Capital Group,s 2016 Disruptive Growth ... at 2:15 p.m. ET on Wednesday, February 10, 2016.  ... taking place at 3:15 p.m. ET. http://www.aethlonmedical.com .  ... after the conclusion of the live event. The panel discussion ...
(Date:2/5/2016)... 2016  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... underwritten secondary offering of 11,027,558 shares of its common ... of Blackstone and Goldman Sachs.  The shares are being ... $96.45 per share. The selling stockholders will receive all ... nor any of its directors, officers or other stockholders ...
Breaking Medicine Technology: